Our new client DisperSol Technologies, Inc. (https://www.dispersoltech.com/) is a private, Austin, Texas-based drug development company which utilizes its patented KinetiSol technology to solve some of the most challenging bioavailability issues related to small molecule drugs. One of these products is KDFX (also known as DST-0509), a KinetiSol enhanced formulation of Deferasirox,the approved iron chelation drug and the active ingredient in Exjade® & Jadenu®, for treating iro
Glycostem Therapeutics B.V. (“Glycostem” or the “Company”). Glycostem is a cell therapy company focused on developing stem cell-derived Natural Killer cells (NK cells) to treat cancer. Due to their tightly regulated “natural killing” of cancer cells, NK cells are the new star in the domain of cellular immunotherapy. They play an important role in treating hematological malignancies, like Acute Myeloid Leukemia (AML), Multiple Myeloma (MM) and possibly solid tumors. The Sage G
Conceptomed, an innovative Norwegian based medtech company, has created SalivaPOD™ for easy-to-use saliva sample collection. SalivaPOD™ is now sold throughout Scandinavia by a leading distributor of laboratory supplies and equipment. Conceptomed looks to expand its distribution and partnering network in Europe, the US, Asia, Latin America, Australia, and elsewhere. The Sage Group is advising Conceptomed on business development in respect of partnering and licensing globally.